IRIS
BELLI, Carmen
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.027
NA - Nord America 1.120
EU - Europa 498
SA - Sud America 457
Continente sconosciuto - Info sul continente non disponibili 145
AF - Africa 65
OC - Oceania 7
Totale 4.319
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.046
SG - Singapore 768
CN - Cina 400
BR - Brasile 322
VN - Vietnam 301
IT - Italia 221
HK - Hong Kong 169
BD - Bangladesh 95
FR - Francia 62
KR - Corea 54
IN - India 50
DE - Germania 49
AR - Argentina 47
FI - Finlandia 44
NL - Olanda 31
IQ - Iraq 30
ZA - Sudafrica 23
EC - Ecuador 22
CA - Canada 21
GB - Regno Unito 20
MY - Malesia 18
TR - Turchia 18
MX - Messico 17
RU - Federazione Russa 17
VE - Venezuela 17
CO - Colombia 15
ID - Indonesia 14
PK - Pakistan 14
UZ - Uzbekistan 14
PL - Polonia 13
CL - Cile 12
NP - Nepal 11
KE - Kenya 10
PY - Paraguay 10
MA - Marocco 9
JO - Giordania 8
LT - Lituania 7
SA - Arabia Saudita 7
UA - Ucraina 7
AZ - Azerbaigian 6
PH - Filippine 6
AU - Australia 5
DO - Repubblica Dominicana 5
ES - Italia 5
GE - Georgia 5
HN - Honduras 5
JM - Giamaica 5
KZ - Kazakistan 5
PE - Perù 5
TT - Trinidad e Tobago 5
UY - Uruguay 5
CI - Costa d'Avorio 4
CR - Costa Rica 4
GT - Guatemala 4
IL - Israele 4
JP - Giappone 4
ET - Etiopia 3
IE - Irlanda 3
OM - Oman 3
PT - Portogallo 3
RS - Serbia 3
SN - Senegal 3
SY - Repubblica araba siriana 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
BH - Bahrain 2
BO - Bolivia 2
CH - Svizzera 2
DZ - Algeria 2
EG - Egitto 2
IR - Iran 2
KG - Kirghizistan 2
LA - Repubblica Popolare Democratica del Laos 2
LB - Libano 2
NI - Nicaragua 2
PA - Panama 2
SV - El Salvador 2
TN - Tunisia 2
TW - Taiwan 2
XK - ???statistics.table.value.countryCode.XK??? 2
AM - Armenia 1
BB - Barbados 1
BE - Belgio 1
BG - Bulgaria 1
BW - Botswana 1
CG - Congo 1
CM - Camerun 1
GH - Ghana 1
GR - Grecia 1
HU - Ungheria 1
KH - Cambogia 1
KW - Kuwait 1
LK - Sri Lanka 1
MD - Moldavia 1
MK - Macedonia 1
MZ - Mozambico 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PF - Polinesia Francese 1
QA - Qatar 1
Totale 4.170
Salva come PNG Salva come JPEG
Città #
Singapore 309
San Jose 197
Council Bluffs 170
Hong Kong 166
Ashburn 110
Boardman 106
Ho Chi Minh City 106
Beijing 84
Hefei 81
Hanoi 67
Seoul 53
Florence 49
Lauterbourg 45
Shanghai 43
Milan 42
Santa Clara 40
Helsinki 39
Dallas 37
Phoenix 32
New York 25
São Paulo 25
Haiphong 22
Munich 21
Ogden 21
Rome 21
Los Angeles 19
Falkenstein 16
Amsterdam 15
Rio de Janeiro 13
Tashkent 13
Baghdad 12
Da Nang 12
Warsaw 12
Kuala Lumpur 11
Biên Hòa 10
Chicago 10
Frankfurt am Main 9
Belo Horizonte 8
Johannesburg 8
London 8
The Dalles 8
Amman 7
Caracas 7
Istanbul 7
Lahore 7
Mumbai 7
Campinas 6
Dhaka 6
Guayaquil 6
Nairobi 6
Quito 6
Asunción 5
Baku 5
Bologna 5
Brasília 5
Cape Town 5
Chennai 5
Curitiba 5
Goiânia 5
Hải Dương 5
Lappeenranta 5
Lima 5
Montevideo 5
Moscow 5
New Delhi 5
Omaha 5
Abidjan 4
Blumenau 4
Brooklyn 4
Buenos Aires 4
Buffalo 4
Diadema 4
Gorle 4
Guarulhos 4
Guatemala City 4
Kilburn 4
Manchester 4
Mexico City 4
Ninh Bình 4
Orem 4
Osasco 4
Paola 4
Phú Thọ 4
Pittsburgh 4
Bauru 3
Belgrade 3
Boston 3
Can Tho 3
Cotia 3
Dakar 3
Denver 3
Erbil 3
Guangzhou 3
Hillsboro 3
Jeddah 3
Johor Bahru 3
Joinville 3
Kathmandu 3
Kingston 3
Mauá 3
Totale 2.355
Salva come PNG Salva come JPEG
Nome #
Variant allele frequency: a decision-making tool in precision oncology? 161
Expression of the oncoproteins p16, p53 and Ki67 as predictive value in the differentiation of low-grade intracervical neoplasms of high and low risk 139
Development and Validation of a Serum Metabolomic Signature for Endometrial Cancer Screening in Postmenopausal Women 127
Malignant pleural mesothelioma: Current treatments and emerging drugs 123
A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: Cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen) 115
ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research 113
Safety of covid-19 mrna vaccines in patients with cancer enrolled in early-phase clinical trials 108
Capecitabine with/without mitomycin C: Results of a randomized phase II trial of second-line therapy in advanced biliary tract adenocarcinoma 108
Breast metastases from oligodendroglioma: An unusual extraneural spread in two young women and a review of the literature 99
Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden 96
Clinical significance of skin toxicity due to EGFR-targeted Therapies 94
Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study) 90
(Ir)relevance of metformin treatment in patients with metastatic pancreatic cancer: An open-label, randomized phase II trial 88
Association between baseline tumour burden and outcome in patients with cancer treated with next-generation immunoncology agents 88
Molecular tumour board at European Institute of Oncology: Report of the first three year activity of an Italian precision oncology experience 85
Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: A phase II randomised trial 85
Serum vascular endothelial growth factor (VEGF) levels correlate with tumor VEGF and p53 overexpression in endocrine positive primary breast cancer 84
The Pan-Immune-Inflammation Value in microsatellite instability–high metastatic colorectal cancer patients treated with immune checkpoint inhibitors 84
Clinical efficacy of ribociclib as a first-line therapy for HR-positive, advanced breast cancer 83
Beyond PD(L)-1 Blockade in Microsatellite-Instable Cancers: Current Landscape of Immune Co-Inhibitory Receptor Targeting 82
Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directions 81
Targeting Cellular Components of the Tumor Microenvironment in Solid Malignancies 80
Targeting the microenvironment in solid tumors 80
Baseline Tumor Size as Prognostic Index in Patients With Advanced Solid Tumors Receiving Experimental Targeted Agents 79
Evaluation of the Geographical Accessibility of Genome-Matched Clinical Trials on a National Experience 79
Evidence for interleukin 17 involvement in severe immune-related neuroendocrine toxicity 79
Liver toxicity in the era of immune checkpoint inhibitors: A practical approach 79
Adjuvant treatment in biliary tract cancer: To treat or not to treat? 78
Immunomodulatory agents with antivascular activity in the treatment of non-small cell lung cancer: Focus on TLR9 agonists, IMiDs and NGR-TNF 75
The evolving landscape of ‘next-generation’ immune checkpoint inhibitors: A review 74
A demand-offer critical analysis of current drug development. Phase I drugs versus TCGA sequencing data 74
The emerging role of PI3K inhibitors for solid tumour treatment and beyond 71
Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors 71
Homologous recombination deficiency in triple negative breast cancer 69
Will antiangiogenic agents be a future for mesothelioma therapy? 68
Estrogen receptor (ER) and epidermal growth factor receptor (EGFR) as targets for dual lung cancer therapy: Not just a case? 67
Antiangiogenic strategies in breast cancer management 67
Immune-Related Adverse Event Likelihood Score Identifies “Pure” IRAEs Strongly Associated With Outcome in a Phase I-II Trial Population 63
Neoadjuvant therapy in resectable pancreatic cancer: A critical review 58
Progresses toward precision medicine in RET-altered solid tumors 58
XELIRI or FOLFIRI as salvage therapy in advanced pancreatic cancer 58
Phase II trial of salvage therapy with trabectedin in metastatic pancreatic adenocarcinoma 56
The return of RET GateKeeper mutations? an in-silico exploratory analysis of potential resistance mechanisms to novel RET macrocyclic inhibitor TPX-0046 55
Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer 55
Role of taxanes in pancreatic cancer 54
Translational therapies for malignant pleural mesothelioma 53
Second-line therapy in advanced biliary tract cancer: What should be the standard? 51
Tumori del polmone 51
Mesoteliona Pleurico 50
Malignant Mesothelioma 49
Unity is strength: One, two, or more drugs against advanced pancreatic cancer? 49
Neo-adjuvant and adjuvant chemotherapy of gastric cancer 48
Mesotelioma Pleurico 29
Genomic and clinical landscape of metastatic hormone receptors-positive breast cancers carrying ESR1 alterations 28
Deleterious alterations in homologous recombination repair genes and efficacy of platinum-based chemotherapy in biliary tract cancers 20
The Safety and Suitability of DNA Sequencing of Tissue Biopsies Performed on Patients Referred to a Phase I Unit 20
Effect of age on safety and efficacy of novel cancer drugs investigated in early-phase clinical trials 19
The evolving landscape of metastatic HER2-positive, hormone receptor-positive Breast Cancer 14
Unfavorable carcinoma of unknown primary with a gastrointestinal profile: a retrospective study 14
Cancers of Unknown Primary Origin: Real-World Clinical Outcomes and Genomic Analysis at the European Institute of Oncology 13
Interstitial lung disease in patients enrolled in early-phase clinical trials: the ILDE study 13
Clinical actionability of BRCA2 alterations in uterine leiomyosarcoma: a molecular tumor board case report and a cBioPortal comprehensive analysis 11
Peritoneal effusion: an uncommon adverse effect of selective RET inhibitors 7
Totale 4.319
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.343
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.343
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/2023194 0 0 0 0 0 0 0 0 140 5 49 0
2023/2024200 5 1 27 8 15 6 8 32 35 13 14 36
2024/20251.006 36 114 23 42 47 106 15 70 155 31 85 282
2025/20262.597 325 116 105 200 507 147 306 169 169 213 137 203
2026/2027322 226 83 13 0 0 0 0 0 0 0 0 0
Totale 4.319